Press Releases - Genentech
WEBDec 6, 2010 · Genentech Announces Positive Phase III Results for Inavolisib Combination in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation. 21 Nov 2023. Genentech and NVIDIA Enter Into Strategic AI Research Collaboration to Accelerate Drug Discovery and Development. 26 Oct 2023.
FDA Approves Genentech’s Tecentriq Hybreza, the First and Only ...
WEBSep 12, 2024 · SOUTH SAN FRANCISCO, Calif., September 12, 2024--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved ...
FDA Grants Breakthrough Therapy Designation to Genentech’s …
WEBMay 21, 2024 · FDA Grants Breakthrough Therapy Designation to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation. Business Wire. Tue, May 21,...
Genentech and NVIDIA Enter Into Strategic AI Research …
WEBNov 21, 2023 · Genentech scientists aim to glean new insights for target and drug discovery and to answer fundamental questions about human biology and disease.
Genentech: Press Releases | Thursday, Apr 18, 2024
WEBApr 18, 2024 · FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer. Approval based on Phase III ALINA study showing Alecensa reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage resected non-small cell lung cancer (NSCLC)
Genentech: Press Releases | Tuesday, May 28, 2024
WEBMay 28, 2024 · FDA Grants Priority Review to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation. Priority Review recognizes the best-in-class potential of the inavolisib-based regimen for patients in urgent need of new treatment options.
Genentech receives FDA approval for cancer treatment
WEBSep 12, 2024 5:10pm. By Connor Hart. Genentech has received Food and Drug Administration approval for its treatment of certain types of lung, liver, skin and soft tissue cancer in adults. The ...
Genentech and NVIDIA Enter Into Strategic AI Research …
WEBNov 21, 2023 · The companies will join forces to accelerate and optimize Genentech’s proprietary machine learning (ML) algorithms and models on NVIDIA DGX Cloud, which provides a training-as-a-service...
Nvidia Looks to Genentech for Its Next Leap in AI Drug Discovery
WEBNov 28, 2023 · In its new partnership with Nvidia, Genentech plans to accelerate and optimize its machine learning (ML) algorithms and models through NVIDIA DGX™ Cloud, designed to facilitate generative AI ...
FDA Approves Genentech's Alecensa as First Adjuvant Treatment …
WEBApr 18, 2024 · SOUTH SAN FRANCISCO, Calif., April 18, 2024--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved...